Orchard Therapeutics develops autologous ex vivo gene therapies to treat rare, life-threatening genetic diseases. Its approach collects a patient’s hematopoietic stem cells, edits a functional gene outside the body, and reinserts the corrected cells to rebuild the blood and immune system. The company differentiates itself by delivering single-dose, patient-specific cures that aim to address the disease at its source, with Libmeldy/Lenmeldy as its approved product and a clinical-stage pipeline for other conditions. Orchard’s goal is to provide safe, one-time therapies for children with severe genetic disorders and to expand a portfolio of approved and investigational gene therapies through its Kyowa Kirin ownership.
Company Size
201-500
Company Stage
IPO
Headquarters
London, United Kingdom
Founded
2015
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?